(AMPX) Amprius Technologies - NYSE
Sector: Industrials | Industry: Electrical Equipment & Parts | Exchange: NYSE (USA) | Market Cap: 2.164m USD | Total Return: 296.8% in 12m
Avg Turnover: 143M
Qual. Beats: -1
Rev. Trend: 99.7%
Qual. Beats: 5
Warnings
Share dilution 16.1% YoY
Choppy Below Avwap Earnings
Tailwinds
Rs Leader
Amprius Technologies, Inc. (AMPX) specializes in the development and production of high-energy density lithium-ion batteries, utilizing a proprietary silicon anode technology. Its primary product lines, SiCore and SiMaxx, are engineered for mobility sectors with a specific focus on aviation, including drones and high-altitude pseudo satellites (HAPS).
The company operates within the advanced battery manufacturing sector, where silicon anodes are favored over traditional graphite to theoretically increase energy capacity and reduce charging times. This business model relies on securing design wins within the aerospace and defense industries, where weight-to-power ratios are critical performance metrics. For deeper insights into these technical specifications and market positioning, ValueRay offers additional data points.
Founded in 2008 and based in Fremont, California, Amprius functions as a key player in the transition toward electrified flight. The company’s growth is closely tied to the scaling of its manufacturing capacity to meet the rigorous demands of both military and commercial unmanned aerial systems.
- Silicon anode commercialization milestones drive revenue growth in aviation markets
- Production scale-up at Colorado facility impacts capital expenditure and margins
- High-altitude pseudo satellite contract wins validate proprietary silicon nanowire technology
- Expansion into electric vehicle sector diversifies revenue beyond niche drone applications
- Dependence on specialized material suppliers creates potential supply chain volatility
| Net Income: -39.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.45 > 0.02 and ΔFCF/TA -12.91 > 1.0 |
| NWC/Revenue: 108.5% < 20% (prev 157.5%; Δ -48.98% < -1%) |
| CFO/TA -0.42 > 3% & CFO -54.3m > Net Income -39.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 7.13 > 1.5 & < 3 |
| Outstanding Shares: last quarter (136.9m) vs 12m ago 16.09% < -2% |
| Gross Margin: 18.13% > 18% (prev -49.06%; Δ 67.19% > 0.5%) |
| Asset Turnover: 72.43% > 50% (prev 27.95%; Δ 44.47% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.75 (Total Current Assets 114.0m - Total Current Liabilities 16.0m) / Total Assets 130.8m |
| B: -1.71 (Retained Earnings -223.4m / Total Assets 130.8m) |
| C: -0.17 (EBIT TTM -21.1m / Avg Total Assets 124.6m) |
| D: 5.12 (Book Value of Equity 109.4m / Total Liabilities 21.4m) |
| Altman-Z'' = 3.58 = A |
| DSRI: 1.24 (Receivables 35.3m/10.4m, Revenue 90.3m/33.1m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.04 (AQ_t 0.00 / AQ_t-1 0.01) |
| SGI: 2.73 (Revenue 90.3m / 33.1m) |
| TATA: 0.11 (NI -39.7m - CFO -54.3m) / TA 130.8m) |
| Beneish M = -2.14 (Cap -4..+1) = BB |
As of June 19, 2026, the stock is trading at USD 16.17 with a total of 7,718,527 shares traded.
Over the past week, the price has changed by -8.70%,
over one month by -5.48%,
over three months by -22.60% and
over the past year by +296.83%.
Amprius Technologies has received a consensus analysts rating of 4.43. Therefore, it is recommended to buy AMPX.
- StrongBuy: 4
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 22.1 | 36.9% |
P/S = 26.3914
P/B = 21.7721
Revenue TTM = 90.3m USD
EBIT TTM = -21.1m USD
EBITDA TTM = -17.0m USD
Long Term Debt = 5.39m USD (estimated: total debt 6.56m - short term 1.17m)
Short Term Debt = 1.17m USD (from shortTermDebt, last quarter)
Debt = 6.56m USD (from shortLongTermDebtTotal, last quarter) (leases 6.56m already included)
Net Debt = -55.8m USD (calculated: Debt 6.56m - CCE 62.4m)
Enterprise Value = 2.11b USD (2.16b + Debt 6.56m - CCE 62.4m)
Interest Coverage Ratio = unknown (Ebit TTM -21.1m / Interest Expense TTM 0.0)
EV/FCF = -35.89x (Enterprise Value 2.11b / FCF TTM -58.8m)
FCF Yield = -2.79% (FCF TTM -58.8m / Enterprise Value 2.11b)
FCF Margin = -65.09% (FCF TTM -58.8m / Revenue TTM 90.3m)
Net Margin = -43.98% (Net Income TTM -39.7m / Revenue TTM 90.3m)
Gross Margin = 18.13% ((Revenue TTM 90.3m - Cost of Revenue TTM 73.9m) / Revenue TTM)
Gross Margin QoQ = 20.11% (prev 23.65%)
Tobins Q-Ratio = 16.12 (Enterprise Value 2.11b / Total Assets 130.8m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 6.56m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -16.7m (EBIT -21.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 7.13 (Total Current Assets 114.0m / Total Current Liabilities 16.0m)
Debt / Equity = 0.06 (Debt 6.56m / totalStockholderEquity, last quarter 109.4m)
Debt / EBITDA = 3.29 (negative EBITDA) (Net Debt -55.8m / EBITDA -17.0m)
Debt / FCF = 0.95 (negative FCF - burning cash) (Net Debt -55.8m / FCF TTM -58.8m)
Total Stockholder Equity = 98.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -31.85% (Net Income -39.7m / Total Assets 130.8m)
RoE = -40.40% (Net Income TTM -39.7m / Total Stockholder Equity 98.3m)
RoCE = -20.39% (EBIT -21.1m / Capital Employed (Equity 98.3m + L.T.Debt 5.39m))
RoIC = -14.98% (negative operating profit) (NOPAT -16.7m / Invested Capital 111.5m)
WACC = 14.10% (E(2.16b)/V(2.17b) * Re(14.14%) + D(6.56m)/V(2.17b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 14.14% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 100.00 | Cagr: 21.40%
[DCF] Fair Price = unknown (Cash Flow -58.8m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -1.37 | # QB: -1
Revenue Correlation: 99.72 | Revenue CAGR: 208.8% | SUE: 1.85 | # QB: 5
EPS current Quarter (2026-06-30): EPS=-0.02 | Chg30d=N/A | Revisions=+0% | Analysts=6
EPS next Quarter (2026-09-30): EPS=-0.01 | Chg30d=N/A | Revisions=N/A | Analysts=5
EPS current Year (2026-12-31): EPS=-0.06 | Chg30d=+7.05% | Revisions=+0% | GrowthEPS=+63.5% | GrowthRev=+81.2%
EPS next Year (2027-12-31): EPS=0.06 | Chg30d=-43.85% | Revisions=-20% | GrowthEPS=+193.6% | GrowthRev=+56.6%
[Analyst] Revisions Ratio: -20%